{"organizations": [], "uuid": "59b2da2cc2009711eb0573b26b661afd24bc63e3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 298}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/gsk-advair-novartis/drugmaker-gsk-wins-fresh-advair-reprieve-as-novartis-copy-delayed-idUSL8N1PY2M5", "country": "US", "domain_rank": 408, "title": "Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-02-08T16:31:00.000+02:00", "replies_count": 0, "uuid": "59b2da2cc2009711eb0573b26b661afd24bc63e3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/gsk-advair-novartis/drugmaker-gsk-wins-fresh-advair-reprieve-as-novartis-copy-delayed-idUSL8N1PY2M5", "ord_in_thread": 0, "title": "Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed", "locations": [], "entities": {"persons": [{"name": "ben hirschler", "sentiment": "none"}, {"name": "edmund blair", "sentiment": "none"}], "locations": [{"name": "advair", "sentiment": "none"}, {"name": "london", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "glaxosmithkline", "sentiment": "negative"}, {"name": "novartis", "sentiment": "negative"}, {"name": "gsk", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "sandoz", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON, Feb 8 (Reuters) - GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis’s Sandoz division.\nThe Swiss drugmaker said in an emailed statement on Thursday it had received a so-called complete response letter from the U.S. Food and Drug Administration (FDA) and a generic Advair launch this year was now “highly unlikely”.\nSuch letters from the FDA typically outline concerns and conditions that must be addressed to gain U.S. approval. (Reporting by Ben Hirschler; Editing by Edmund Blair)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-08T16:31:00.000+02:00", "crawled": "2018-02-09T16:59:21.044+02:00", "highlightTitle": ""}